Therapeutic Response
HER2-negative and PD-L1 (CPS) >= 5 status confers therapeutic sensitivity to Capecitabine in combination with Nivolumab and Oxaliplatin in patients with Esophageal Adenocarcinoma.
Statements
| Source and description |
|---|
HER2-negative and PD-L1 (CPS) >= 5 status confers therapeutic sensitivity to Capecitabine in combination with Nivolumab and Oxaliplatin in patients with Esophageal Adenocarcinoma.
| Source and description |
|---|